Evaluation of concurrent chemoradiotherapy for locally advanced NSCLC according to EGFR mutation status-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evaluation of concurrent chemoradiotherapy for locally advanced NSCLC according to EGFR mutation status

Published:2017-05-23 Issue:1 Volume:14 Page:885-890
ISSN:1792-1074
Container-title:Oncology Letters
language:en
Short-container-title:

Author:

Ishihara Mikiko,Igawa Satoshi,Sasaki Jiichiro,Otani Sakiko,Fukui Tomoya,Ryuge Shinichiro,Katono Ken,Hiyoshi Yasuhiro,Kasajima Masashi,Mitsufuji Hisashi,Kubota Masaru,Yokoba Masanori,Katagiri Masato,Sekiguchi Akane,Soda Itaru,Ishiyama Hiromichi,Hayakawa Kazushige,Masuda Noriyuki

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Durvalumab after chemoradiotherapy in non‐small cell lung cancer with EGFR mutation: A real‐world study (HOT2101);Cancer Science;2024-01-29

2. Treatment patterns and survival analysis in patients with unresectable stage III EGFR-mutated non-small cell lung cancer;Aging;2024-01-11

3. Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives;Lung Cancer;2024-01

4. Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer;Expert Review of Anticancer Therapy;2023-08-13

5. Efficacy of first-line tyrosine kinase inhibitor between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer patients;Aging;2023-06-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP